Dividend Assets Capital LLC Sells 2,862 Shares of Becton, Dickinson and Company (NYSE:BDX)


Share on StockTwits

Dividend Assets Capital LLC lowered its holdings in Becton, Dickinson and Company (NYSE:BDX) by 23.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,352 shares of the medical instruments supplier’s stock after selling 2,862 shares during the quarter. Dividend Assets Capital LLC’s holdings in Becton, Dickinson and were worth $2,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of BDX. IHT Wealth Management LLC purchased a new stake in Becton, Dickinson and during the third quarter valued at $209,000. Strs Ohio increased its position in Becton, Dickinson and by 10.6% during the third quarter. Strs Ohio now owns 165,060 shares of the medical instruments supplier’s stock valued at $38,406,000 after acquiring an additional 15,838 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services increased its position in Becton, Dickinson and by 2.4% in the fourth quarter. First National Bank of Mount Dora Trust Investment Services now owns 23,776 shares of the medical instruments supplier’s stock worth $5,950,000 after buying an additional 553 shares in the last quarter. Woodstock Corp bought a new position in Becton, Dickinson and during the fourth quarter valued at approximately $221,000. Finally, Creative Financial Designs Inc. ADV boosted its stake in Becton, Dickinson and by 267,400.0% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 2,675 shares of the medical instruments supplier’s stock valued at $669,000 after buying an additional 2,674 shares during the last quarter. Institutional investors own 83.22% of the company’s stock.

Shares of Becton, Dickinson and stock traded down $1.82 on Tuesday, hitting $251.30. The company’s stock had a trading volume of 4,604 shares, compared to its average volume of 1,312,288. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.07 and a current ratio of 1.54. Becton, Dickinson and Company has a 1 year low of $219.50 and a 1 year high of $284.97. The company has a market capitalization of $73.02 billion, a price-to-earnings ratio of 92.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The firm has a fifty day moving average price of $247.90 and a 200-day moving average price of $246.48.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The company had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same period in the previous year, the firm posted $2.65 EPS. Becton, Dickinson and’s revenue was up 25.8% compared to the same quarter last year. As a group, analysts forecast that Becton, Dickinson and Company will post 12.5 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 30th. Investors of record on Wednesday, June 9th will be issued a $0.83 dividend. This represents a $3.32 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date of this dividend is Tuesday, June 8th. Becton, Dickinson and’s dividend payout ratio is presently 32.55%.

BDX has been the topic of several recent analyst reports. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price target on the stock. in a report on Wednesday, January 13th. Citigroup increased their price target on Becton, Dickinson and from $273.00 to $280.00 and gave the stock a “neutral” rating in a report on Friday, February 5th. Raymond James raised their price objective on Becton, Dickinson and from $270.00 to $282.00 and gave the stock an “outperform” rating in a report on Friday, January 29th. Piper Sandler increased their target price on Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 4th. Finally, TheStreet raised Becton, Dickinson and from a “c+” rating to an “a-” rating in a research report on Thursday, February 4th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $281.08.

Becton, Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.